Intelligence / Healthtech / De Novo Grants / Roche Diagnostics
Approvalsnovel device granted (FDA De Novo)20 Oct 2026
Roche Diagnostics
20 Oct 2026: Novel device granted (FDA De Novo) · Elecsys HBsAg II quant II RxDx. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 20 Oct 2026
- Device
- Elecsys HBsAg II quant II RxDx
- Specialty
- Microbiology
- Product Code
- SJM
- Country
- United States
- Location
- Indianapolis, IL
- Submitted
- 2026-06-02
- Reference
- DEN260027
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Roche Diagnostics
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Roche Diagnostics in our registers.
20 OctRoche Diagnosticsdevice cleared · HealthtechApprovals2 OctRoche Diagnosticsdevice cleared · HealthtechApprovals2 OctRoche Diagnosticsdevice cleared · HealthtechApprovals2 OctRoche Diagnosticsdevice cleared · HealthtechApprovals19 AugRoche Diagnosticsdevice cleared · HealthtechApprovals5 NovRoche Diagnostics Corporationwon a public contract ($1.5M) · HealthtechProcurement
More in Microbiology
De Novo Grants
9 MayTeal Health, Inc.novel device granted (FDA De Novo) · Teal WandApprovals28 MarVisby Medical, Inc.novel device granted (FDA De Novo) · Visby Medical Women's Sexual Health TestApprovals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.